2024
Outcomes and Recurrence Rates Among Patients With Provoked and Cryptogenic Cerebral Venous Thrombosis
Al Kasab S, Almallouhi E, Shu L, Kicielinski K, Salehi Omran S, Liebeskind D, Zubair A, Vedovati M, Paciaroni M, Antonenko K, Heldner M, de Havenon A, Henninger N, Yaghi S. Outcomes and Recurrence Rates Among Patients With Provoked and Cryptogenic Cerebral Venous Thrombosis. Neurology Clinical Practice 2024, 15: e200381. PMID: 39399562, PMCID: PMC11464219, DOI: 10.1212/cpj.0000000000200381.Peer-Reviewed Original ResearchRisk of recurrent venous thromboembolismRecurrent venous thromboembolismCerebral venous thrombosisVenous thromboembolismFemale patientsVenous thrombosisBaseline characteristicsOutcome of cerebral venous thrombosisRate of recurrent venous thromboembolismProvoking factorsRare cause of strokeTransient provoking factorsKaplan-Meier survival analysisDuration of anticoagulationOutcomes of patientsMann-Whitney <i>Cause of strokeConsecutive patientsRare causeRecurrence rateMale patientsMulticenter studyRetrospective databaseStandard treatmentCox regressionPrevalence and Associations of Dural Arteriovenous Fistulae in Cerebral Venous Thrombosis: Analysis of ACTION-CVT
Shoskes A, Shu L, Nguyen T, Abdalkader M, Giles J, Amar J, Siegler J, Henninger N, ElNazeir M, Al Kasab S, Klein P, Heldner M, Antonenko K, Psychogios M, Liebeskind D, Field T, Liberman A, Esenwa C, Simpkins A, Li G, Frontera J, Kuohn L, Rothstein A, Khazaal O, Aziz Y, Mistry E, Khatri P, Omran S, Zubair A, Sharma R, Starke R, Morcos J, Romano J, Yaghi S, Asdaghi N. Prevalence and Associations of Dural Arteriovenous Fistulae in Cerebral Venous Thrombosis: Analysis of ACTION-CVT. Journal Of Stroke 2024, 26: 325-329. PMID: 38836280, PMCID: PMC11164588, DOI: 10.5853/jos.2023.02264.Peer-Reviewed Original ResearchExternal validation of the SI2NCAL2C score for outcomes following cerebral venous thrombosis
Klein P, Shu L, Lindgren E, de Winter M, Siegler J, Simpkins A, Omran S, Heldner M, de Havenon A, Abdalkader M, Al Kasab S, Stretz C, Wu T, Wilson D, Asad S, Almallouhi E, Frontera J, Kuohn L, Rothstein A, Bakradze E, Henninger N, Zubair A, Sharma R, Kerrigan D, Aziz Y, Mistry E, van Kammen M, Tatlisumak T, Krzywicka K, Aguiar de Sousa D, Jood K, Field T, Yaghi S, Coutinho J, Nguyen T. External validation of the SI2NCAL2C score for outcomes following cerebral venous thrombosis. Journal Of Stroke And Cerebrovascular Diseases 2024, 33: 107720. PMID: 38614162, DOI: 10.1016/j.jstrokecerebrovasdis.2024.107720.Peer-Reviewed Original ResearchConceptsCerebral venous thrombosisArea under the receiver operating characteristic curvePoor outcomeVenous thrombosisCentral nervous system infectionInternational retrospective studyNervous system infectionExternal validation cohortFocal neurological deficitsReceiver operating characteristic curvePoor outcome dataLevels of hemoglobinLack of follow-upPoorer outcome scoresConsecutive patientsClinical presentationRetrospective studyValidation cohortIntracerebral hemorrhageNeurological deficitsFollow-upOutcome scoresSystemic infectionLevels of glucoseInternational cohort
2023
Timing and Predictors of Recanalization After Anticoagulation in Cerebral Venous Thrombosis
Omran S, Shu L, Chang A, Parikh N, Zubair A, Simpkins A, Heldner M, Hakim A, Al Kasab S, Nguyen T, Klein P, Goldstein E, Vedovati M, Paciaroni M, Liebeskind D, Yaghi S, Cutting S. Timing and Predictors of Recanalization After Anticoagulation in Cerebral Venous Thrombosis. Journal Of Stroke 2023, 25: 291-298. PMID: 37282376, PMCID: PMC10250867, DOI: 10.5853/jos.2023.00213.Peer-Reviewed Original ResearchCerebral venous thrombosisPredictors of recanalizationVenous thrombosisMale sexMultivariable analysisParenchymal changesOlder ageTiming of recanalizationVenous thrombosis studyLarge prospective studiesCVT diagnosisFurther recanalizationComplete recanalizationAnticoagulation treatmentConsecutive patientsDisease courseIndependent predictorsVessel recanalizationBaseline imagingInitial diagnosisMedian timeProspective studyPrespecified variablesThrombosis StudyFavorable outcome
2022
Predictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis
Shu L, Bakradze E, Omran SS, Giles J, Amar J, Henninger N, Elnazeir M, Liberman A, Moncrieffe K, Rotblat J, Sharma R, Cheng Y, Zubair AS, Simpkins A, Li G, Kung J, Perez D, Heldner MR, Scutelnic A, von Martial R, Siepen B, Rothstein A, Khazaal O, Do D, Al Kasab S, Rahman LA, Mistry EA, Kerrigan D, Lafever H, Nguyen TN, Klein P, Aparicio HJ, Frontera JA, Kuohn L, Agarwal S, Stretz C, Kala N, ElJamal S, Chang A, Cutting S, Indraswari F, de Havenon A, Muddasani V, Wu T, Wilson D, Nouh A, Asad D, Qureshi A, Moore J, Khatri P, Aziz Y, Casteigne B, Khan M, Cheng Y, Grory BM, Weiss M, Ryan D, Vedovati MC, Paciaroni M, Siegler J, Kamen S, Yu S, Guerrero CL, Atallah E, De Marchis GM, Brehm A, Dittrich T, Psychogios M, Alvarado-Dyer R, Kass-Hout T, Prabhakaran S, Honda T, Liebeskind D, Furie K, Yaghi S. Predictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis. Neurology 2022, 99: e2368-e2377. PMID: 36123126, PMCID: PMC9687409, DOI: 10.1212/wnl.0000000000201122.Peer-Reviewed Original ResearchConceptsCerebral venous thrombosisRecurrent venous thrombosisHistory of VTEVenous thrombosisVenous thromboembolismAntiphospholipid antibodiesBlack raceDiagnosis of CVTPositive antiphospholipid antibodiesRecurrent venous thrombosesAntiphospholipid antibody syndromeRecurrent venous thromboembolismCox regression analysisRisk of recurrenceMulticenter international studyAntibody syndromeOral anticoagulationVenous thrombosesConsecutive patientsRare causeMean ageTreatment strategiesThrombosisPatientsSecondary analysisDirect Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study
Yaghi S, Shu L, Bakradze E, Omran S, Giles JA, Amar JY, Henninger N, Elnazeir M, Liberman AL, Moncrieffe K, Lu J, Sharma R, Cheng Y, Zubair AS, Simpkins AN, Li GT, Kung JC, Perez D, Heldner M, Scutelnic A, Seiffge D, Siepen B, Rothstein A, Khazaal O, Do D, Al Kasab S, Rahman LA, Mistry EA, Kerrigan D, Lafever H, Nguyen TN, Klein P, Aparicio H, Frontera J, Kuohn L, Agarwal S, Stretz C, Kala N, Jamal S, Chang A, Cutting S, Xiao H, de Havenon A, Muddasani V, Wu T, Wilson D, Nouh A, Asad SD, Qureshi A, Moore J, Khatri P, Aziz Y, Casteigne B, Khan M, Cheng Y, Mac Grory B, Weiss M, Ryan D, Vedovati MC, Paciaroni M, Siegler JE, Kamen S, Yu S, Guerrero C, Atallah E, De Marchis GM, Brehm A, Dittrich T, Psychogios M, Alvarado-Dyer R, Kass-Hout T, Prabhakaran S, Honda T, Liebeskind DS, Furie K. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. Stroke 2022, 53: 728-738. PMID: 35143325, DOI: 10.1161/strokeaha.121.037541.Peer-Reviewed Original ResearchConceptsCerebral venous thrombosisDirect oral anticoagulantsVenous thrombosisRecurrent venous thrombosisMajor hemorrhageInclusion criteriaDirect Oral Anticoagulants Versus WarfarinMulticenter international retrospective studyInverse probabilityInternational retrospective studySystemic venous thrombosisFavorable safety profileCox regression modelMulticenter international studyAnalysis inclusion criteriaBaseline imaging dataCVT patientsOral anticoagulationComplete recanalizationDOAC treatmentOral anticoagulantsRadiological outcomesRadiographic outcomesVersus WarfarinWarfarin treatment